logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Heather A. Parsons

Harvard University
H指数:26
被引数:4,358

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

与转移性乳腺癌一线抗HER2为基础治疗中表现出非凡疗效相关的临床特征：来自ESME国家队列的真实世界数据

Breast
IF7.9
2026-10-130
OA
Thomas Grinda; Matthieu Carton; Stefania Morganti; Audrey Mailliez; Christelle Levy; Thierry Petit; Thomas Bachelot; Monica Arnedos; Véronique Diéras; Vincent Massard; Florence Dalenc; Isabelle Desmoulins; Jean-Yves Pierga; Anthony Gonçalves; Caroline Bailleux; Jean-Sebastien Frenel; Lise Bosquet; Heather A. Parsons; William Jacot; Nancy U. Lin
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding

糖皮质激素–FAS轴调控转移定植期间的免疫逃逸

Nature
IF48.5
2026-03-040
PRE
Monica Cassandras; Xavier Sanchez; Lauren Hsu; Yu Huang; Adam J. Getzler; Debolina Ganguly; Pilar Baldominos; Ia Codinachs; Jeffrey Chuong; Elizabeth E. Martin; Blake E. Smith; Eleonora Marina; Milos Spasic; Xingping Qin; Heather A. Parsons; Erica L. Mayer; Kristopher A. Sarosiek; Stephanie K. Dougan; Elizabeth A. Mittendorf; Sandra S. McAllister; Ya-Chieh Hsu; Judith Agudo
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer☆

生存结局及DNADX ctDNA检测在应用sacituzumab govitecan治疗转移性乳腺癌患者中的作用☆

ESMO Open
IF8.3
2025-09-300
OAAI
S. Morganti; R.J. Kusmick; M.E. Hughes; F. Brasó-Maristany; K. Smith; P. Tarantino; R. Vega-Leon; T. Grinda; F. Pardo; K. Dvir; G.L. Suggs; S. Buck; M. Skeffington; A.C. Garrido-Castro; H.A. Parsons; S.L. Sammons; A. Prat; N.U. Lin; S.M. Tolaney; A. Giordano
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

检测细胞游离DNA中酪氨酸激酶抑制剂异质性耐药机制

Cell Genomics
IF9
2025-09-090
OAAI
Heather A. Parsons; Conor Messer; Katheryn Santos; Jakob Weiss; David Merrell; Brian P. Danysh; Melissa E. Hughes; Gregory J. Kirkner; Ashka Patel; Julian Hess; Kerry Sendrick; Chip Stewart; Elizabeth Grant; Kristy Schlueter-Kuck; Albert Grinshpun; Nikhil Wagle; Jamunarani Veeraraghavan; Jose Pablo Leone; Rachel A. Freedman; Otto Metzger; Rachel Schiff; Eric P. Winer; Sara M. Tolaney; Mothaffar Rimawi; Ian E. Krop; Gad Getz; Nancy U. Lin
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

一项关于奈拉替尼联合或不联合氟维司群治疗HER2阳性、雌激素受体阳性转移性乳腺癌的随机II期研究

Clinical Breast Cancer
IF2.5
2025-05-160
PRE
Stefania Morganti; Xiangying Chu; Tarah J. Ballinger; Nisha Unni; Sarah Sinclair; Robert Wesolowski; Alyssa M. Pereslete; Paulina Lange; Nabihah Tayob; Nancy U. Lin; Jose P. Leone; Ian E. Krop; Sara M. Tolaney; Heather A. Parsons
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis

循环肿瘤DNA清除作为接受新辅助免疫检查点抑制剂治疗的实体瘤患者病理完全缓解的预测生物标志物：一项系统评价和荟萃分析

Annals of Oncology
IF65.4
2025-04-030
PRE
C. Valenza; E.F. Saldanha; Y. Gong; P. De Placido; D. Gritsch; H. Ortiz; D. Trapani; F. Conforti; C. Cremolini; S. Peters; J. Mateo; V. Subbiah; H.A. Parsons; A.H. Partridge; G. Curigliano
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

循环肿瘤DNA在早期三阴性乳腺癌中的作用：一项系统评价和Meta分析

BREAST CANCER RESEARCH
IF5.6
2025-03-120
OA
Zhang, Diana; Jahanfar, Shayesteh; Rabinowitz, Judy B.; Dower, Joshua; Song, Fei; Wu, Cherng-Horng; Hu, Xiao; Tracy, Phillip; Basik, Mark; Medford, Arielle; Lin, Po-Han; Huang, Chiun-Sheng; Bidard, Francois-Clement; Renault, Shufang; Pai, Lori; Buss, Mary; Parsons, Heather A.; Schlam, Ilana
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

I期研究：评估ribociclib（CDK4/6抑制剂）联合sparatalizumab（PD-1抑制剂），并分别联用或未联用fulvestrant，用于激素受体阳性转移性乳腺癌或晚期卵巢癌。

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2025-02-252
OA
Garrido-Castro, Ana C.; Graham, Noah; Ali, Lestat R.; Herold, Christina; Desrosiers, Jennifer; Do, Khanh; Parsons, Heather; Li, Tianyu; Dilullo, Molly; Wrabel, Eileen; Williams, Amy J.; Liu, Joyce F.; Mittendorf, Elizabeth A.; Dougan, Stephanie K.; Tayob, Nabihah; Shapiro, Geoffrey I.; Tolaney, Sara M.
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Neratinib和ado-曲妥珠单抗emtansine用于预处理和未治疗的人表皮生长因子受体2 (HER2) 阳性乳腺癌脑转移: 转化乳腺癌研究联盟试验022

ANNALS OF ONCOLOGY
IF65.4
2024-11-011
OAAI
Freedman, R. A.; Heiling, H. M.; Li, T.; Trapani, D.; Tayob, N.; Smith, K. L.; Davis, R.; Pereslete, A. M.; Demeo, M. K.; Cotter, C.; Chen, W. Y.; Parsons, H. A.; Santa-Maria, C. A.; Van Poznak, C.; Moy, B.; Brufsky, A. M.; Melisko, M. E.; o'Sullivan, C. C.; Ashai, N.; Rauf, Y.; Nangia, J. R.; Burns, R. T.; Savoie, J.; Wolff, A. C.; Winer, E. P.; Rimawi, M. F.; Krop, I. E.; Lin, N. U.
Real-world activity of sacituzumab govitecan for metastatic breast cancer

Sacituzumab govitecan在转移性乳腺癌中的真实世界应用

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Morganti, S.; Kusmick, R.; Hughes, M. E.; Braso-Maristany, F.; Smith, K.; Tarantino, P.; Vega Leon, M. D. R.; Grinda, T.; Pardo, F.; Dvir, K.; Suggs, G.; Buck, S.; Skeffington, M.; Garrido-Castro, A. C.; Parsons, H.; Sammons, S.; Prat, A.; Lin, N.; Tolaney, S. M.; Giordano, A.
OptimICE-RD: sacituzumab govitecan plus pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Optimice-rd: sacituzumab govitecan加pembrolizumab与pembrolizumab (± 卡培他滨) 治疗残留的三阴性乳腺癌

FUTURE ONCOLOGY
IF2.6
2024-06-263
OAAI
Tolaney, Sara M.; DeMichele, Angela; Takano, Toshimi; Rugo, Hope S.; Perou, Charles; Lynce, Filipa; Parsons, Heather Anne; Santa-Maria, Cesar Augusto; Rocque, Gabrielle Betty; Yao, Wenliang; Sun, Shawn W.; Mocci, Simonetta; Partridge, Ann H.; Carey, Lisa A.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study (vol 15, 2691, 2024)
NATURE COMMUNICATIONS
IF15.7
2024-05-100
OAAI
Lynce, Filipa; Mainor, Candace; Donahue, Renee N.; Geng, Xue; Jones, Greg; Schlam, Ilana; Wang, Hongkun; Toney, Nicole J.; Jochems, Caroline; Schlom, Jeffrey; Zeck, Jay; Gallagher, Christopher; Nanda, Rita; Graham, Deena; Stringer-Reasor, Erica M.; Denduluri, Neelima; Collins, Julie; Chitalia, Ami; Tiwari, Shruti; Nunes, Raquel; Kaltman, Rebecca; Khoury, Katia; Gatti-Mays, Margaret; Tarantino, Paolo; Tolaney, Sara M.; Swain, Sandra M.; Pohlmann, Paula; Parsons, Heather A.; Isaacs, Claudine
Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Parsons, Heather; Baca, Sylvan; D'Ippolito, Anthony; Jeong, Hyun-Hwan; Smith, Kalie; Tarantino, Paolo; Hughes, Melissa; Sendrick, Kerry; Painter, Corrie; Seo, Ji-Heui; Grant, Elizabeth; Guess, Jamey; Davidsohn, Matthew; Lakshminarayanan, Gitanjali; Strauss, Sarah; Savignano, Hunter; Canniff, John; Fortunato, Brad; Eaton, Matthew; Choueiri, Toni; Tolaney, Sara; Freedman, Matthew; Lin, Nancy
Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Goetz, Matthew; Wander, Seth; Bachelot, Thomas; Batist, Gerald; Cortes, Javier; Cristofanilli, Massimo; Curigliano, Giuseppe; de Nonneville, Alexandre; Yam, Einav Nili-Gal; Jhaveri, Komal; Ma, Cynthia; Parsons, Heather; Rugo, Hope; Sammons, Sarah; Stover, Daniel; Twelves, Chris; Bardia, Aditya; Plourde, Paul V.; Portman, David J.; Damodaran, Senthil

研究方向

暂未获取到该数据
N
Nancy U. Lin
H 指数:95论文数:1,074被引数:4.2万
M
Melissa E. Hughes
H 指数:40论文数:365被引数:7,251
S
Sara M. Tolaney
H 指数:83论文数:1,341被引数:3.6万
J
Justin Rhoades
H 指数:18论文数:122被引数:3,771
D
Daniel G. Stover
H 指数:43论文数:458被引数:1.2万
N
Nabihah Tayob
H 指数:35论文数:453被引数:5,459
E
Eric P. Winer
H 指数:170论文数:1,624被引数:12.9万
A
Atish D. Choudhury
H 指数:29论文数:348被引数:5,915
K
Katheryn Santos
H 指数:7论文数:29被引数:407
G
Gavin Ha
H 指数:90论文数:384被引数:7.4万